Strategic Partnerships Position ELIAS to engage with veterinary clinics, veterinary oncologists, and specialty hospitals that treat canine cancers, highlighting ECI as a USDA-approved osteosarcoma therapy and exploring co-development or distribution agreements.

Clinical Expansion Leverage recent conference participation and SAB additions to solicit speaking engagements and collaborative studies with veterinary academic centers, showcasing combined immunotherapy and chemotherapy regimens to widen adoption.

Manufacturing Scale Capitalize on announced facility expansion in Lenexa to pursue partnerships with contract manufacturers, logistics providers, and supply-chain collaborators to ensure scalable production and reliable service for growing veterinary oncology demand.

Strategic Funding Target investor and grant opportunities aligned with immunotherapy for companion animals, using the $10–$25M revenue range and $13M funding background to engage potential strategic investors and co-development financing.

Market Differentiation Highlight the unique autologous vaccine plus cell therapy approach, USDA approval, and ongoing clinical studies to differentiate from competitors like larger animal health players, while offering scalable education and clinical outcome materials to drive adoption.